HomeCompareEPIX vs YUM

EPIX vs YUM: Dividend Comparison 2026

EPIX yields 840.47% · YUM yields 4.00%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPIX wins by $4215412.25M in total portfolio value
10 years
EPIX
EPIX
● Live price
840.47%
Share price
$0.20
Annual div
$1.69
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4215412.28M
Annual income
$3,415,908,279,597.25
Full EPIX calculator →
YUM
YUM
● Live price
4.00%
Share price
$50.00
Annual div
$2.00
5Y div CAGR
5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$899.19
Full YUM calculator →

Portfolio growth — EPIX vs YUM

📍 EPIX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEPIXYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EPIX + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EPIX pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EPIX
Annual income on $10K today (after 15% tax)
$71,440.13/yr
After 10yr DRIP, annual income (after tax)
$2,903,522,037,657.66/yr
YUM
Annual income on $10K today (after 15% tax)
$340.00/yr
After 10yr DRIP, annual income (after tax)
$764.31/yr
At 15% tax rate, EPIX beats the other by $2,903,522,036,893.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EPIX + YUM for your $10,000?

EPIX: 50%YUM: 50%
100% YUM50/50100% EPIX
Portfolio after 10yr
$2107706.15M
Annual income
$1,707,954,140,248.22/yr
Blended yield
81.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

EPIX
Analyst Ratings
2
Buy
3
Hold
Consensus: Hold
Price Target
$9.50
+4621.7% upside vs current
Range: $2.00 — $17.00
Altman Z
1.1
Piotroski
3/9
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+246.3% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EPIX buys
0
YUM buys
0
No recent congressional trades found for EPIX or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEPIXYUM
Forward yield840.47%4.00%
Annual dividend / share$1.69$2.00
Payout ratio50%50%
1-year div growth0%5%
5-year div CAGR0%5%
Portfolio after 10y$4215412.28M$28.0K
Annual income after 10y$3,415,908,279,597.25$899.19
Total dividends collected$4152700.41M$6.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusHoldHold
Analyst price target$9.50$173.15

Year-by-year: EPIX vs YUM ($10,000, DRIP)

YearEPIX PortfolioEPIX Income/yrYUM PortfolioYUM Income/yrGap
1← crossover$94,747$84,047.22$11,120$420.00+$83.6KEPIX
2$845,608$744,228.02$12,357$458.31+$833.3KEPIX
3$7,112,413$6,207,612.95$13,721$499.76+$7.10MEPIX
4$56,406,815$48,796,533.54$15,227$544.58+$56.39MEPIX
5$422,031,389$361,676,096.60$16,885$593.02+$422.01MEPIX
6$2,980,575,750$2,529,002,163.86$18,713$645.34+$2980.56MEPIX
7$19,881,694,862$16,692,478,809.61$20,724$701.81+$19881.67MEPIX
8$125,334,964,899$104,061,551,396.31$22,938$762.73+$125334.94MEPIX
9$747,200,001,618$613,091,589,175.98$25,372$828.41+$747199.98MEPIX
10$4,215,412,281,328$3,415,908,279,597.25$28,047$899.19+$4215412.25MEPIX

EPIX vs YUM: Complete Analysis 2026

EPIXStock

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Full EPIX Calculator →

YUMConsumer Discretionary

YUM is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in YUM shares.

Full YUM Calculator →
📬

Get this EPIX vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EPIX vs SCHDEPIX vs JEPIEPIX vs OEPIX vs KOEPIX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.